Exploring CAR T Updates in Pediatric Acute Lymphoblastic Leukemia

In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy’s (ASTCT) program ASTCT Talks, Terri Lynn Shigle, PharmD, BCOP hosted Vinita Pai, PharmD, MS, BCPPS, who spoke about the use of CAR T-cell therapy for pediatric patients, focusing on acute lymphoblastic leukemia (ALL).After a brief overview of progress in the cellular therapy field and pediatrics’ first and only FDA approved CAR T product since 2017, their discussion explored the following:Review of real-world practice and outcomes in ALLPediatric practical challenges including logistics, leukapheresis, and lymphodepletion chemotherapyStrategies for managing cell therapy toxicities in pediatricpatientsConsiderations for survivorship and long-term toxicitiesGaps in pediatric care and future directionsListen below or via your favorite podcast platform.ReferenceO'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142-1146. doi:10.1158/1078-0432.CCR-18-2035